DOCSLIB.ORG

Table SI. a Total of 643 Proteins Were Identified by Tandem Mass Spectrometry in the Microvesicles/Exosomes from Patients with ABE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table SI. a Total of 643 Proteins Were Identified by Tandem Mass Spectrometry in the Microvesicles/Exosomes from Patients with ABE Table SI. A total of 643 proteins were identified by tandem mass spectrometry in the microvesicles/exosomes from patients with ABE. Accession Description Coverage PS Unique AAs Molecular Calc. pI Abundance ratio: Abundance ratio: Score Sequest no. Peptides Ms Peptides weight (kDa) Moderate/ Severe/ control HT control P01024 Complement C3 85.68851 132 228 127 1663 187.03 6.4 1.12 1.131 8141.004593 1 P0C0L5 Complement C4-B 66.80046 89 128 1 1744 192.631 7.27 2.106 1.249 4859.406727 9 P01023 Alpha-2-macroglobulin 63.83989 76 140 76 1474 163.188 6.46 1.021 0.972 5149.27648 2 P02751 Fibronectin 56.03521 87 960 87 2386 262.46 5.71 0.805 1.005 3458.332983 P02768 Serum albumin 79.31034 54 104 54 609 69.321 6.28 1.157 1.086 3705.267895 4 P08603 Complement factor H 58.4078 60 544 55 1231 139.005 6.61 1.02 0.979 1917.082723 Q9Y6R7 IgGFc-binding protein 27.71508 68 305 68 5405 571.639 5.34 1.527 1.04 981.3557811 P04114 Apolipoprotein B-100 33.66206 124 255 124 4563 515.283 7.05 1.055 1.057 753.3890735 Q12860 Contactin-1 56.87623 46 242 46 1018 113.249 5.9 0.747 0.963 816.1462975 A0A0A0M Immunoglobulin heavy 55.6391 23 124 12 399 43.884 6.96 1.206 1.104 4833.498744 S08 constant gamma 1 (Fragment) 7 P01031 Complement C5 44.98807 66 254 66 1676 188.186 6.52 1.224 1.241 804.1478994 P23142 Fibulin-1 57.32575 26 297 10 703 77.162 5.22 0.812 0.946 1110.052139 O00533 Neural cell adhesion molecule 42.88079 38 220 37 1208 134.987 5.76 0.789 0.827 804.1383946 L1-like protein B4DPQ0 cDNA FLJ54471, highly 53.82476 30 278 30 719 81.837 6.37 0.995 0.971 923.9868439 similar to Complement C1r subcomponent (EC 3.4.21.41) B1AHL2 Fibulin-1 45.21498 22 313 6 721 78.277 5.39 0.738 0.874 1163.650674 P12111 Collagen alpha-3(VI) chain 28.0768 67 142 1 3177 343.457 6.68 1.317 1.101 483.426379 E7ENL6 Collagen alpha-3(VI) chain 34.41028 67 142 1 2569 277.946 8.18 0.891 0.884 483.3237839 P09871 Complement C1s 50.72674 27 217 26 688 76.635 4.96 1.046 0.992 778.6229264 subcomponent P02787 Serotransferrin 58.88252 41 155 41 698 77.014 7.12 0.913 0.967 532.2420925 P02647 Apolipoprotein A-I 77.15356 24 385 24 267 30.759 5.76 1.315 1.057 1253.797316 P02675 Fibrinogen beta chain 71.2831 28 168 28 491 55.892 8.27 1.531 1.35 564.475502 P10643 Complement component C7 50.05931 29 156 29 843 93.457 6.48 0.712 0.872 573.7836608 A0A286YE Immunoglobulin heavy 54.43038 17 719 8 395 43.778 6.52 1.565 0.874 2565.892901 Y4 constant gamma 2 (Fragment) Q99435 Protein kinase C-binding 49.63235 30 216 30 816 91.284 5.73 0.846 0.823 715.4273092 protein NELL2 P22105 Tenascin-X 28.26497 72 124 72 4242 457.932 5.17 0.939 1.003 393.8049548 B4E1Z4 cDNA FLJ55673, highly 39.9684 46 160 29 1266 140.853 7.18 0.612 0.611 494.6025889 similar to Complement factor B (EC 3.4.21.47) P01860 Immunoglobulin heavy 61.00796 20 778 8 377 41.26 7.9 0.814 0.785 2633.157825 constant gamma 3 Q92823 Neuronal cell adhesion 37.88344 35 146 35 1304 143.8 5.66 0.798 0.878 513.597772 molecule Q15113 Procollagen C-endopeptidase 57.23831 21 185 21 449 47.942 7.43 0.916 1.052 723.5592999 enhancer 1 P00747 Plasminogen 47.16049 36 139 36 810 90.51 7.24 1.17 1.084 485.4632403 P13645 Keratin, type I cytoskeletal 10 62.84247 32 125 29 584 58.792 5.21 0.767 0.9 416.226961 P02452 Collagen alpha-1(I) chain 23.01913 25 186 25 1464 138.857 5.8 0.879 0.96 644.1995287 P02649 Apolipoprotein E 80.12618 30 492 30 317 36.132 5.73 0.877 1.037 1639.833651 A0A286YF Immunoglobulin heavy 49.49495 14 371 6 396 43.804 6.24 1.412 1.43 1384.943221 J8 constant gamma 4 (Fragment) P06396 Gelsolin 43.47826 28 173 28 782 85.644 6.28 0.852 0.91 630.3224766 Q7Z7M0 Multiple epidermal growth 20.0703 40 121 40 2845 302.901 6.87 0.785 1.009 432.9133862 factor-like domains protein 8 P14543 Nidogen-1 41.94066 38 129 37 1247 136.291 5.29 0.883 1.072 452.404595 E7ERL8 Neurexin-1-beta 36.09821 39 126 28 1507 165.341 5.96 0.802 0.996 392.0663251 P24043 Laminin subunit alpha-2 21.10826 58 100 58 3122 343.684 6.4 0.877 0.94 306.6071104 P06727 Apolipoprotein A-IV 75.75758 31 154 31 396 45.371 5.38 0.481 0.587 511.2329108 Q08380 Galectin-3-binding protein 44.2735 22 188 22 585 65.289 5.27 0.777 1.24 656.6998068 Q15063 Periostin 51.07656 34 103 3 836 93.255 7.53 0.921 1.074 346.0569105 B1ALD9 Periostin 49.75248 32 102 1 808 90.087 7.94 0.926 0.956 337.5734499 P04264 Keratin, type II cytoskeletal 1 43.47826 27 137 24 644 65.999 8.12 0.737 0.926 416.9153267 E7EUF1 Ectonucleotide 35.181 26 116 26 884 101.488 7.53 0.804 1.155 414.4653013 pyrophosphatase/phosphodies terase family member 2 P08123 Collagen alpha-2(I) chain 21.52269 22 125 22 1366 129.235 8.95 0.915 0.975 444.3861085 P01834 Immunoglobulin kappa 80.37383 6 655 6 107 11.758 6.52 1.299 1.106 2588.88807 constant P02671 Fibrinogen alpha chain 32.10162 24 118 24 866 94.914 6.01 1.342 1.368 365.6363721 A0A0A0M Receptor-type tyrosine-protein 25.31561 25 87 3 1505 168.814 6.48 0.859 0.887 297.8582029 R60 phosphatase S Q12805 EGF-containing fibulin-like 50.10142 19 91 5 493 54.604 5.07 0.84 1.058 345.0832398 extracellular matrix protein 1 P55058 Phospholipid transfer protein 43.61055 17 88 17 493 54.705 7.01 1.004 1.027 322.0597194 P10909 Clusterin 37.86192 19 259 19 449 52.461 6.27 0.728 1.193 816.842995 P00734 Prothrombin 49.19614 24 71 24 622 69.992 5.9 0.876 0.832 257.8331151 Q86VB7 Scavenger receptor cysteine- 34.77509 29 98 29 1156 125.369 5.95 1.115 0.757 329.5928527 rich type 1 protein M130 Q13332 Receptor-type tyrosine-protein 18.94251 23 80 1 1948 216.905 6.46 0.9 1.113 268.2885706 phosphatase S Q15582 Transforming growth factor- 46.99854 23 92 23 683 74.634 7.71 1.039 1.077 302.8436617 beta-induced protein ig-h3 M0R0Q9 Complement C3 (Fragment) 84.15842 6 130 1 101 11.148 4.77 0.981 1.178 506.8810011 P02461 Collagen alpha-1(III) chain 15.27967 19 125 18 1466 138.479 6.61 1.027 0.951 404.4664441 P0DOY2 Immunoglobulin lambda 93.39623 9 391 2 106 11.287 7.24 1.149 0.946 1610.298396 constant 2 P02679 Fibrinogen gamma chain 52.98013 22 105 14 453 51.479 5.62 1.478 1.394 307.4672016 G3XAI2 Laminin subunit beta-1 26.79558 39 77 39 1810 200.347 4.96 0.84 0.879 235.8733978 P51693 Amyloid-like protein 1 28.61538 18 106 18 650 72.131 5.8 0.746 0.922 398.4112236 Q9P2S2 Neurexin-2 26.10981 37 96 33 1712 184.865 5.92 0.844 1.013 317.2764077 A0A0B4J23 Immunoglobulin lambda-like 49.76744 10 315 3 215 23.136 8.84 0.884 0.984 1260.790692 1 polypeptide 5 P14618 Pyruvate kinase PKM 52.54237 24 79 9 531 57.9 7.84 1.047 0.948 286.2856965 P01034 Cystatin-C 62.32877 8 103 8 146 15.789 8.75 0.764 1.149 433.4969542 Q92859 Neogenin 23.54552 29 70 29 1461 159.917 6.54 0.851 0.99 225.9264209 P10586 Receptor-type tyrosine-protein 19.45464 26 60 11 1907 212.744 6.3 0.879 0.955 218.8161631 phosphatase F P23468 Receptor-type tyrosine-protein 19.66527 27 61 2 1912 214.625 6.57 0.749 0.821 204.8723233 phosphatase delta A0A1W2P Contactin-2 31.6129 24 61 24 1085 118.208 7.55 0.846 1.038 210.001472 Q11 P35908 Keratin, type II cytoskeletal 2 51.3302 28 89 20 639 65.393 8 0.733 0.834 274.1373594 epidermal Q3KPI9 PTPRD protein 24.06417 26 59 1 1496 168.559 6.71 0.885 0.903 197.0752573 A0A0U1RR Neurexin-3-beta 23.9338 29 72 24 1571 173.549 6.15 0.888 0.979 209.8694506 J0 P35527 Keratin, type I cytoskeletal 9 39.9679 21 74 20 623 62.027 5.24 0.81 0.925 218.3285863 O14594 Neurocan core protein 19.15216 23 77 22 1321 143.003 5.38 0.866 0.936 253.315281 A0A0U1RQ EGF-containing fibulin-like 72.5 15 69 1 280 31.736 6.62 0.935 1.024 257.903069 V3 extracellular matrix protein 1 (Fragment) P36955 Pigment epithelium-derived 46.17225 16 74 16 418 46.283 6.38 0.959 1.027 253.0521644 factor O94985 Calsyntenin-1 26.91131 25 69 25 981 109.724 4.91 0.873 0.964 212.9554882 P98160 Basement membrane-specific 9.678889 31 59 31 4391 468.532 6.51 0.936 0.983 185.1466975 heparan sulfate proteoglycan core protein P13671 Complement component C6 35.11777 25 61 25 934 104.718 6.76 1.002 1.028 192.3045006 P01009 Alpha-1-antitrypsin 46.65072 20 69 20 418 46.707 5.59 0.889 0.827 223.3318003 H3BR70 Pyruvate kinase 55.7377 19 62 4 366 40.164 8.03 0.867 0.891 216.4689045 P19827 Inter-alpha-trypsin inhibitor 26.78375 18 58 18 911 101.326 6.79 1.088 0.901 202.5168812 heavy chain H1 P06681 Complement C2 34.17553 24 62 7 752 83.214 7.42 1.09 1.018 210.9730308 P19823 Inter-alpha-trypsin inhibitor 28.96406 23 69 23 946 106.397 6.86 1.071 1.006 213.0384146 heavy chain H2 V9GYM3 Apolipoprotein A-II 48.1203 7 104 7 133 14.905 8.27 1.219 1.338 382.2305138 P11047 Laminin subunit gamma-1 21.44189 31 53 31 1609 177.489 5.12 0.79 0.879 167.0971448 B7ZKJ8 ITIH4 protein 29.30481 22 57 22 935 103.816 6.89 0.976 0.855 195.2793177 P32004 Neural cell adhesion molecule 28.00318 31 58 30 1257 139.915 6.24 0.816 0.997 165.0750264 L1 P07358 Complement component C8 35.8714 17 46 17 591 67.003 8.13 0.913 1.098 151.0469677 beta chain P12109 Collagen alpha-1(VI) chain 26.84825 22 56 22 1028 108.462 5.43 0.869 1.101 173.1234797 P04004 Vitronectin 33.2636 13 89 13 478 54.271 5.8 0.875 1.018 282.3141191 P35555 Fibrillin-1 14.45489 34 52 32 2871 312.022 4.93 0.902 0.98 135.9623934 Q96GW7 Brevican core protein 32.05269 21 54 20 911 99.056 4.64 0.863 1.219 142.861371 P01871 Immunoglobulin heavy 52.98013 19 67 19 453 49.409 6.77 1.057 1.12 209.8624344 constant mu A0A0A0M Coagulation factor V 14.35621 26 52 26 2229 252.078 6.05 0.884 1.031 140.9423827 RJ7 Q8TEU8 WAP, Kazal, immunoglobulin, 33.50694 15 41 15 576 63.898 6.21 0.767 0.78 130.4619564 Kunitz and NTR domain- containing protein 2 Q14112 Nidogen-2 18.98182 22 46 4 1375 151.158 5.29 0.939 1.007 149.3320858 Q16610 Extracellular matrix protein 1 37.40741 15
Load more

Recommended publications
  • The Significance of the Evolutionary Relationship of Prion Proteins and ZIP Transporters in Health and Disease
    The Significance of the Evolutionary Relationship of Prion Proteins and ZIP Transporters in Health and Disease by Sepehr Ehsani A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by Sepehr Ehsani 2012 The Significance of the Evolutionary Relationship of Prion Proteins and ZIP Transporters in Health and Disease Sepehr Ehsani Doctor of Philosophy Department of Laboratory Medicine and Pathobiology University of Toronto 2012 Abstract The cellular prion protein (PrPC) is unique amongst mammalian proteins in that it not only has the capacity to aggregate (in the form of scrapie PrP; PrPSc) and cause neuronal degeneration, but can also act as an independent vector for the transmission of disease from one individual to another of the same or, in some instances, other species. Since the discovery of PrPC nearly thirty years ago, two salient questions have remained largely unanswered, namely, (i) what is the normal function of the cellular protein in the central nervous system, and (ii) what is/are the factor(s) involved in the misfolding of PrPC into PrPSc? To shed light on aspects of these questions, we undertook a discovery-based interactome investigation of PrPC in mouse neuroblastoma cells (Chapter 2), and among the candidate interactors, identified two members of the ZIP family of zinc transporters (ZIP6 and ZIP10) as possessing a PrP-like domain. Detailed analyses revealed that the LIV-1 subfamily of ZIP transporters (to which ZIPs 6 and 10 belong) are in fact the evolutionary ancestors of prions (Chapter 3).
    [Show full text]
  • The Extracellular Matrix: an Accomplice in Gastric Cancer Development and Progression
    cells Review The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression Ana Margarida Moreira 1,2,3, Joana Pereira 1,2,4, Soraia Melo 1,2,4 , Maria Sofia Fernandes 1,2, Patrícia Carneiro 1,2 , Raquel Seruca 1,2,4 and Joana Figueiredo 1,2,* 1 Epithelial Interactions in Cancer Group, i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal; [email protected] (A.M.M.); [email protected] (J.P.); [email protected] (S.M.); [email protected] (M.S.F.); [email protected] (P.C.); [email protected] (R.S.) 2 Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal 3 Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal 4 Medical Faculty, University of Porto, 4200-319 Porto, Portugal * Correspondence: jfi[email protected]; Tel.: +351-220408800; Fax: +351-225570799 Received: 15 January 2020; Accepted: 6 February 2020; Published: 8 February 2020 Abstract: The extracellular matrix (ECM) is a dynamic and highly organized tissue structure, providing support and maintaining normal epithelial architecture. In the last decade, increasing evidence has emerged demonstrating that alterations in ECM composition and assembly strongly affect cellular function and behavior. Even though the detailed mechanisms underlying cell-ECM crosstalk are yet to unravel, it is well established that ECM deregulation accompanies the development of many pathological conditions, such as gastric cancer. Notably, gastric cancer remains a worldwide concern, representing the third most frequent cause of cancer-associated deaths. Despite increased surveillance protocols, patients are usually diagnosed at advanced disease stages, urging the identification of novel diagnostic biomarkers and efficient therapeutic strategies.
    [Show full text]
  • Bruch's Membrane Abnormalities in PRDM5-Related Brittle Cornea
    Porter et al. Orphanet Journal of Rare Diseases (2015) 10:145 DOI 10.1186/s13023-015-0360-4 RESEARCH Open Access Bruch’s membrane abnormalities in PRDM5-related brittle cornea syndrome Louise F. Porter1,2,3, Roberto Gallego-Pinazo4, Catherine L. Keeling5, Martyna Kamieniorz5, Nicoletta Zoppi6, Marina Colombi6, Cecilia Giunta7, Richard Bonshek2,8, Forbes D. Manson1 and Graeme C. Black1,9* Abstract Background: Brittle cornea syndrome (BCS) is a rare, generalized connective tissue disorder associated with extreme corneal thinning and a high risk of corneal rupture. Recessive mutations in transcription factors ZNF469 and PRDM5 cause BCS. Both transcription factors are suggested to act on a common pathway regulating extracellular matrix genes, particularly fibrillar collagens. We identified bilateral myopic choroidal neovascularization as the presenting feature of BCS in a 26-year-old-woman carrying a novel PRDM5 mutation (p.Glu134*). We performed immunohistochemistry of anterior and posterior segment ocular tissues, as expression of PRDM5 in the eye has not been described, or the effects of PRDM5-associated disease on the retina, particularly the extracellular matrix composition of Bruch’smembrane. Methods: Immunohistochemistry using antibodies against PRDM5, collagens type I, III, and IV was performed on the eyes of two unaffected controls and two patients (both with Δ9-14 PRDM5). Expression of collagens, integrins, tenascin and fibronectin in skin fibroblasts of a BCS patient with a novel p.Glu134* PRDM5 mutation was assessed using immunofluorescence. Results: PRDM5 is expressed in the corneal epithelium and retina. We observe reduced expression of major components of Bruch’s membrane in the eyes of two BCS patients with a PRDM5 Δ9-14 mutation.
    [Show full text]
  • Loss of the Dermis Zinc Transporter ZIP13 Promotes the Mildness Of
    www.nature.com/scientificreports OPEN Loss of the dermis zinc transporter ZIP13 promotes the mildness of fbrosarcoma by inhibiting autophagy Mi-Gi Lee1,8, Min-Ah Choi2,8, Sehyun Chae3,8, Mi-Ae Kang4, Hantae Jo4, Jin-myoung Baek4, Kyu-Ree In4, Hyein Park4, Hyojin Heo4, Dongmin Jang5, Sofa Brito4, Sung Tae Kim6, Dae-Ok Kim 1,7, Jong-Soo Lee4, Jae-Ryong Kim2* & Bum-Ho Bin 4* Fibrosarcoma is a skin tumor that is frequently observed in humans, dogs, and cats. Despite unsightly appearance, studies on fbrosarcoma have not signifcantly progressed, due to a relatively mild tumor severity and a lower incidence than that of other epithelial tumors. Here, we focused on the role of a recently-found dermis zinc transporter, ZIP13, in fbrosarcoma progression. We generated two transformed cell lines from wild-type and ZIP13-KO mice-derived dermal fbroblasts by stably expressing the Simian Virus (SV) 40-T antigen. The ZIP13−/− cell line exhibited an impairment in autophagy, followed by hypersensitivity to nutrient defciency. The autophagy impairment in the ZIP13−/− cell line was due to the low expression of LC3 gene and protein, and was restored by the DNA demethylating agent, 5-aza-2’-deoxycytidine (5-aza) treatment. Moreover, the DNA methyltransferase activity was signifcantly increased in the ZIP13−/− cell line, indicating the disturbance of epigenetic regulations. Autophagy inhibitors efectively inhibited the growth of fbrosarcoma with relatively minor damages to normal cells in xenograft assay. Our data show that proper control over autophagy and zinc homeostasis could allow for the development of a new therapeutic strategy to treat fbrosarcoma.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • MA Identifier Upordown LFC Avgexpr T P Value P Corrected
    MA_Identifier UpOrDown LFC AvgExpr t p_value p_corrected mRNA_Accession mRNA_Name AGT_Accession GD214292.1 Up 2.09674838 10.60378749 30.17940104 1.3532E-12 4.15339E-08 No Good Match No Good Match TR73477|c2_g4_i1 EB253690.1 Up 1.42056324 8.629454582 16.9400776 8.61647E-10 4.15339E-08 No Good Match No Good Match TR114624|c0_g1_i1 EB324506.1 Up 1.714877372 11.7626061 29.56600148 1.62329E-12 4.15339E-08 XM_013079935 uncharacterized LOC101862711, transcript variant X2 TR105757|c1_g1_i3 EB244298.1 Up 1.504941765 13.13555745 25.49705172 8.54949E-12 6.17912E-08 XM_005093725 uncharacterized LOC101862711, transcript variant X3 TR105757|c1_g1_i1 EB350631.1 Up 1.951725495 13.11211692 23.57801356 2.22739E-11 1.45399E-07 No Good Match No Good Match TR674|c0_g1_i1 EB250403.1 Up 2.236254197 12.79847784 21.59049993 6.28948E-11 3.48034E-07 No Good Match No Good Match TR107643|c0_g1_i1 EB229658.1 Up 1.196239323 12.26876042 18.23277846 3.64746E-10 5.66891E-07 No Good Match No Good Match CL455Contig2 EB349970.1 Up 0.915715907 13.66977042 17.25614464 6.50486E-10 8.43055E-07 No Good Match No Good Match TR112158|c9_g9_i1 EB215450.1 Down -0.779710678 9.573335222 -15.07554052 2.88601E-09 1.03781E-06 No Good Match No Good Match TR81289|c1_g1_i5 EB256532.1 Up 0.957584438 12.63905003 15.56227553 2.07024E-09 1.19669E-06 No Good Match No Good Match TR64854|c4_g1_i2 EB261386.1 Up 0.771865585 7.532393475 13.39242509 1.06221E-08 1.19669E-06 No Good Match No Good Match TR87266|c0_g1_i1 EB323709.1 Up 0.993428329 8.843840926 14.33197647 5.17673E-09 1.19669E-06 XM_013085446
    [Show full text]
  • 9-Azido Analogs of Three Sialic Acid Forms for Metabolic Remodeling Of
    Supporting Information 9-Azido Analogs of Three Sialic Acid Forms for Metabolic Remodeling of Cell-Surface Sialoglycans Bo Cheng,†,‡ Lu Dong,†,§ Yuntao Zhu,†,‡ Rongbing Huang,†,‡ Yuting Sun,†,‖ Qiancheng You,†,‡ Qitao Song,†,§ James C. Paton, ∇ Adrienne W. Paton,∇ and Xing Chen*,†,‡,§,⊥,# †College of Chemistry and Molecular Engineering, ‡Beijing National Laboratory for Molecular Sciences, §Peking−Tsinghua Center for Life Sciences,‖Academy for Advanced Interdisciplinary Studies, ⊥Synthetic and Functional Biomolecules Center, and #Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Peking University, Beijing 100871, China ∇Research Centre for Infectious Diseases, Department of Molecular and Biomedical Science, University of Adelaide, Adelaide SA 5005, Australia Page S1 Table of Contents: Scheme S1.……………………………………………………….........……………. S3 Figure S1……………………………………………………..………..……………. S3 Figure S2……………………………………………………..………..…………… S4 Figure S3……………………………………………………..………..…………… S4 Figure S4……………………………………………………..………..…………… S5 Figure S5……………………………………………………..………..…………… S6 Figure S6……………………………………………………..………..…………….S7 Figure S7……………………………………………………..………..…………….S8 Figure S8……………………………………………………..………..…………….S9 Experimental Procedures……………………………….…........…………....S10-S27 Table S1………………………………………………..………..…………….S28-S48 Supporting Reference……………………………………………….......………...S49 Page S2 Scheme S1. Synthesis of 9AzNeu5Gc Figure S1: a, b, c, d) Representative scatter plots (FSC vs. SSC) and histograms of flow cytometry analysis
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]
  • Transcriptomic and Proteomic Profiling Provides Insight Into
    BASIC RESEARCH www.jasn.org Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy † † ‡ Peidi Liu,* Emelie Lassén,* Viji Nair, Celine C. Berthier, Miyuki Suguro, Carina Sihlbom,§ † | † Matthias Kretzler, Christer Betsholtz, ¶ Börje Haraldsson,* Wenjun Ju, Kerstin Ebefors,* and Jenny Nyström* *Department of Physiology, Institute of Neuroscience and Physiology, §Proteomics Core Facility at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden; †Division of Nephrology, Department of Internal Medicine and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan; ‡Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan; |Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; and ¶Integrated Cardio Metabolic Centre, Karolinska Institutet Novum, Huddinge, Sweden ABSTRACT IgA nephropathy (IgAN), the most common GN worldwide, is characterized by circulating galactose-deficient IgA (gd-IgA) that forms immune complexes. The immune complexes are deposited in the glomerular mesangium, leading to inflammation and loss of renal function, but the complete pathophysiology of the disease is not understood. Using an integrated global transcriptomic and proteomic profiling approach, we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsy specimens from patients with IgAN (n=19) and controls (n=22). Using curated glomerular cell type–specific genes from the published literature, we found differential expression of a much higher percentage of mesangial cell–positive standard genes than podocyte-positive standard genes in IgAN. Principal coordinate analysis of expression data revealed clear separation of patient and control samples on the basis of mesangial but not podocyte cell–positive standard genes.
    [Show full text]
  • Identification of Biomarker Responses in Humans Under Experimentally Induced Zinc Depletion
    IDENTIFICATION OF BIOMARKER RESPONSES IN HUMANS UNDER EXPERIMENTALLY INDUCED ZINC DEPLETION By MOON-SUHN RYU A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2011 1 © 2011 Moon-Suhn Ryu 2 To my parents, Ji-Chul Ryu and Soon-Young Park, and my grandmother, Jung-Seo Seo 3 ACKNOWLEDGMENTS The achievements from the past years in my life as a doctoral student would not exist without the presence of the support and love from my family far way in South Korea. I thank my parents for their love and belief in me which have been the greatest motivation for me to pursue accomplishments and success with my best efforts. I also render my gratefulness to my younger sister, Jin-Suhn Ryu, for being the best supporter in all aspects of my life. Additionally, I thank everyone with whom I shared the moments in the lab, especially, Dr. Juan P. Liuzzi, Dr. Louis A. Lichten, Dr. Liang Guo, Dr. Shou- mei Chang, Tolunay Beker Aydemir, for their invaluable advices and help. The excitement from our findings was always the greatest motivation for me to stay in progress. I also thank Gregory Guthrie, Alyssa Maki, Luisa Rios and Vanessa Da Silva for their cheer and support, particularly, during the last year of my doctoral research. I thank Meena Shankar and the staff members at the General Clinical Research Center for their advices and assistance during the phases of study design and implementation of the dietary regimen.
    [Show full text]
  • The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions Of
    The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions of Pluripotency in Somatic Cells A thesis presented to the faculty of the College of Arts and Sciences of Ohio University In partial fulfillment of the requirements for the degree Master of Science Yuli Hu April 2021 © 2021 Yuli Hu. All Rights Reserved. 2 This thesis titled The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions of Pluripotency in Somatic Cells by YULI HU has been approved for the Department of Biological Sciences and the College of Arts and Sciences by Yang V. Li Professor of Biomedical Sciences Florenz Plassmann Dean, College of Arts and Sciences 3 Abstract YULI HU, M.S., April 2021, Biological Sciences The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions of Pluripotency in Somatic Cells Director of Thesis: Yang V. Li Microenvironmental pH is one of the factors that affect the stability of zinc- protein binding. The tight binding between zinc and proteins is favored by the basic pH, whereas acidic pH favors a loose bound, and treatment of strong acid results in the dissociation of zinc. Physiologically, the stomach uses a very acidic pH to digest food which results in a high amount of soluble zinc in the stomach. Whether or not zinc co- present with acid and the effect of zinc on the gastric lining has rarely been discussed. In my experiments, acidic treatment induced the expression of a pluripotent marker in primary cultured gastric cells. It also stimulated the release of intracellular zinc, suggesting that acidic pH supported protein expression through dynamic zinc regulation.
    [Show full text]
  • Requirement of Zinc Transporter ZIP10 for Epidermal Development: Implication of the ZIP10–P63 Axis in Epithelial Homeostasis
    Requirement of zinc transporter ZIP10 for epidermal development: Implication of the ZIP10–p63 axis in epithelial homeostasis Bum-Ho Bina,1,2, Jinhyuk Bhinb,1, Mikiro Takaishic, Koh-ei Toyoshimad, Saeko Kawamatae, Kana Itoe, Takafumi Harae, Takashi Watanabef, Tarou Iriéa,g, Teruhisa Takagishie, Su-Hyon Leeh, Haeng-Sun Jungh, Sangchul Rhoi, Juyeon Seoj, Dong-Hwa Choik, Daehee Hwangl, Haruhiko Kosekim, Osamu Oharaf, Shigetoshi Sanoc, Takashi Tsujid, Kenji Mishimaa, and Toshiyuki Fukadaa,e,n,2 aDivision of Pathology, Department of Oral Diagnostic Sciences, School of Dentistry, Showa University, Tokyo 142-8555, Japan; bDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; cDepartment of Dermatology, Kochi Medical School, Kochi University, Nankoku 783-8505, Japan; dLaboratory for Organ Regeneration, RIKEN Center for Developmental Biology, Kobe 650-0047, Japan; eMolecular and Cellular Physiology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima 770-8514, Japan; fLaboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan; gDivision of Anatomical and Cellular Pathology, Department of Pathology, Iwate Medical University, Iwate 028-3694, Japan; hBio Solution Corporation, Seoul 139-743, Republic of Korea; iInstitute of Environmental and Energy Technology, Pohang University of Science and Technology, Pohang 37673, Republic of Korea; jAmorepacific R&D Unit, Beauty in Longevity Science Research Division, Beauty Food Research Team, Youngin 17074, Republic of Korea; kGyeonggi Bio Center, Gyeonggi Institute of Science and Technology Promotion, Suwon 443-270, Republic of Korea; lDepartment of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Republic of Korea; mLaboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0042, Japan; and nRIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan Edited by Joan S.
    [Show full text]